Drug Trial Radar · NCT06788912
Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)
Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Mar 20, 2025
Primary completion
Feb 6, 2032
Study completion Feb 6, 2032
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Jan 23, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main goals are after treatment given before surgery, to measure the number of people who have no signs of cancer cells in tumors and lymph nodes removed during surgery; and to learn about whether the cancer gets smaller or goes away by measuring the number of people with a certain number of living cancer cells in the tumor removed during surgery.
Conditions
- Lung Neoplasm Malignant
Interventions
Pembrolizumab (neoadjuvant)Biological
Before surgery neoadjuvant Pembrolizumab 200 mg by intravenous (IV) infusion on day 1 of each 21-day cycle for 4 cycles
CisplatinDrug
Cisplatin 75 mg/m\^2 by IV infusion on day 1 of each 21-day cycle for 4 cycles
GemcitabineDrug
In squamous tumors Gemcitabine 1000 mg/m\^2 by IV infusion on day 1 and day 8 of each 21-day cycle for 4 cycles.
PemetrexedDrug
In nonsquamous tumors Pemetrexed 500 mg/m\^2 by IV infusion on day 1 of each 21-day cycle for 4 cycles
Sacituzumab tirumotecanDrug
Sacituzumab tirumotecan 4 mg/kg by IV infusion on day 1 of each 14-day cycle for up to 6 cycles
H1 receptor antagonistDrug
Administered as rescue medication before Sacituzumab tirumotecan infusion per approved product label
H2 receptor antagonistDrug
Administered as rescue medication before Sacituzumab tirumotecan infusion per approved product label
Acetaminophen (or equivalent)Drug
Administered as rescue medication before Sacituzumab tirumotecan infusion per approved product label
Dexamethasone (or equivalent)Drug
Administered as rescue medication 8 -10 mg before Sacituzumab tirumotecan infusion per approved product label
CarboplatinDrug
AUC 5 mg/mL min or AUC 6 mg/mL min by IV infusion on day 1 of each 21-day cycle for 4 cycles
Pembrolizumab (adjuvant)Biological
After surgery adjuvant Pembrolizumab 200 mg by IV infusion on day 1 of each 21-day cycle for 13 cycles
PaclitaxelDrug
Paclitaxel 175 or 200 mg/m\^2 by IV infusion on day 1 of each 21-day cycle for 4 cycles.
Steroid mouthwash (dexamethasone or equivalent)Drug
Administered orally as rescue medication 2-5 mL 4 times daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pathological Complete Response (pCR)Time frame: Up to approximately 20 weeks
- Percent Residual Viable Tumor (%RVT)Time frame: Up to approximately 20 weeks
Locations
39 sites in 9 countries. Site status is shown where the registry gives one.
Southern Cancer Center (SCC) ( Site 8004)
Daphne, Alabama
Sansum Clinic (Ridley Tree) ( Site 8012)
Santa Barbara, California
Rocky Mountain Cancer Centers (RMCC) ( Site 8011)
Lone Tree, Colorado
Greenebaum Comprehensive Cancer Center ( Site 0402)
Baltimore, Maryland
MedStar Franklin Square Medical Center ( Site 0033)
Baltimore, Maryland
Oncology Associates of Oregon, P.C.(Willamette Valley Cancer Institute) (WVCI) ( Site 8006)
Eugene, Oregon
Texas Oncology - Central/South Texas ( Site 8009)
Austin, Texas
Texas Oncology - Northeast Texas ( Site 8005)
Tyler, Texas
Virginia Cancer Specialists (VCS) ( Site 8002)
Fairfax, Virginia
Centro de Estudios Clínicos SAGA ( Site 0162)
Santiago, Region M. de Santiago, Chile
Fundación Arturo López Pérez ( Site 0161)
Santiago, Region M. de Santiago, Chile
Bradfordhill ( Site 0160)
Santiago, Region M. de Santiago, Chile
Alexandra General Hospital of Athens Oncology-Hematology Unit ( Site 0203)
Athens, Attica, Greece
ATTIKON GENERAL UNIVERSITY HOSPITAL-Oncology ( Site 0202)
Athens, Attica, Greece
Metropolitan Hospital-4th Oncology Dept ( Site 0201)
Athens, Attica, Greece
University General Hospital of Heraklion ( Site 0200)
Heraklion, Irakleio, Greece
Országos Korányi Pulmonológiai Intézet ( Site 0060)
Budapest, Hungary
Petz Aladar Egyetemi Oktato Korhaz-Pulmonológia (Dr. Szalai Zsuzsanna) ( Site 0062)
Győr, Győr-Moson-Sopron, Hungary
Jász-Nagykun-Szolnok Vármegyei Hetényi Géza Kórház-Onkologiai Kozpont ( Site 0061)
Szolnok, Jász-Nagykun-Szolnok, Hungary
Ospedale San Raffaele. ( Site 0171)
Milan, Italy
Fondazione IRCCS Istituto Nazionale dei Tumori ( Site 0175)
Milan, Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Università Cattolica del Sacro Cuore ( Site 0174)
Roma, Italy
Azienda Ospedaliera Universitaria Careggi ( Site 0173)
Florence, Tuscany, Italy
Wielkopolskie Centrum Pulmonologii i Torakochirurgii-Oddzial Onkologii Klinicznej z Pododdzialem Dz ( Site 0153)
Poznan, Greater Poland Voivodeship, Poland
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Nowotworow Pluca i Klatki Pier ( Site 0151)
Warsaw, Masovian Voivodeship, Poland
Uniwersyteckie Centrum Kliniczne-Early Clinical Trials Unit ( Site 0150)
Gdansk, Pomeranian Voivodeship, Poland
Hospital Clinic de Barcelona ( Site 0092)
Barcelona, Spain
Baskent University Dr. Turgut Noyan Research and Training Center-ONCOLOGY ( Site 0702)
Adana, Turkey (Türkiye)
Hacettepe Universite Hastaneleri-oncology hospital ( Site 0700)
Ankara, Turkey (Türkiye)
Akdeniz Universitesi Hastanesi-Medical Oncology ( Site 0704)
Antalya, Turkey (Türkiye)
İzmir Suat Seren Chest Disease Training & Research Hospital ( Site 0701)
Izmir, Turkey (Türkiye)
Ondokuz Mayıs Universitesi-Oncology department ( Site 0706)
Samsun, Turkey (Türkiye)
Shalimov Institute of Surgery and Transplantation ( Site 0138)
Kyiv, Ukraine
CNE CC of Oncology Hematol ( Site 0130)
Cherkasy, Cherkasy Oblast, Ukraine
Municipal Enterprise "Bukovinian сlinical oncology сenter" ( Site 0139)
Chernivtsi, Chernivetska Oblast, Ukraine
CNCE Precarpathian Clinical Oncologic Center ( Site 0131)
Ivano-Frankivsk, Ivano-Frankivsk Oblast, Ukraine
MNPE LTMU Multidisc. Clin. Hosp. of Emerg. and Intens. Care ( Site 0132)
Lviv, Lviv Oblast, Ukraine
ME RIVNE REGIONAL ANTITUMOR CENTER ( Site 0460)
Rivne, Rivne Oblast, Ukraine
Communal Noncommercial Enterprise "Podillia Regional Oncology Center Of Vinnytsia Regional Council" ( Site 0135)
Vinnytsia, Vinnytsia Oblast, Ukraine
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.